



US 20130324438A1

(19) **United States**

(12) **Patent Application Publication**
Berx et al.

(10) **Pub. No.: US 2013/0324438 A1**

(43) **Pub. Date: Dec. 5, 2013**

(54) **METAGENE EXPRESSION SIGNATURE FOR PROGNOSIS OF BREAST CANCER PATIENTS**

Publication Classification

(76) Inventors: **Geert Berx**, Linter-Wommersom (BE);
Eric Raspe, Mouscron (BE)

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
(52) **U.S. Cl.**
CPC **C12Q 1/6886** (2013.01)
USPC **506/10; 506/16; 506/17**

(21) Appl. No.: **13/882,120**

(22) PCT Filed: **Oct. 31, 2011**

(57) **ABSTRACT**

(86) PCT No.: **PCT/EP11/69161**

§ 371 (c)(1),
(2), (4) Date: **Jul. 10, 2013**

(30) **Foreign Application Priority Data**

Oct. 29, 2010 (GB) 1018312.7

Described are gene expression signatures able to distinguish individuals having or suspected to have breast cancer with good clinical prognosis from individuals with poor clinical prognosis, based on ZEB2 transcriptional activity. Further described are kits and assays related to the prognosis and/or the change in prognosis of the individuals suffering from breast cancer.